Sorafenib Neoadjuvant Therapy in the Treatment of High Risk Renal Cell Carcinoma

Abstract

Preoperative neoadjuvant therapy with sorafenib for high risk RCC patients can significantly decrease primary tumor volume as well as tumor thrombus, which could help the nephron-sparing surgery (NSS) or radical nephrectomy to be done successfully.